News

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Executives Dr. Chris Gemmiti and Dr. Rita Barcia to Speak at Cell & Gene Therapy Bioprocessing & Commercialization conference

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Executives Dr. Chris Gemmiti and Dr. Rita Barcia to Speak at Cell & Gene Therapy Bioprocessing & Commercialization Conference

Dr. Chris Gemmiti, VP Operations at Sentien, will be speaking on an Outsourcing vs. Insourcing panel on September 10, 2019.

Dr. Rita Barcia, Executive Director of R&D at Sentien, will be speaking on a Next Generation Therapies panel on September 12, 2019.

Sentien Co-Founder Dr. Biju Parekkadan to Speak at American Society of Gene & Cell Therapy Annual Meeting on 4/29

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Co-Founder Dr. Biju Parekkadan to Speak at American Society of Gene & Cell Therapy Annual Meeting on 4/29

Sentien Biotechnologies Scientific Co-Founder, Dr. Biju Parekkadan, will be speaking at the American Society of Gene & Cell Therapy Annual Meeting on April 29, 2019 in Washington, DC.  He will be discussing Reprogramming Human Immune Responses Using Ex Vivo MSC Bioreactor Therapy.

Meet with us at the 2019 J.P. Morgan Healthcare Conference

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Meet with us at the 2019 J.P. Morgan Healthcare Conference

The Sentien team will be attending the 2019 J.P. Morgan Healthcare Conference. This event continues to be one of the life science industry’s largest conferences of the year. Contact us today to schedule a time to meet with our team and learn more about our business.
SCHEDULE A MEETING >

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Watch Dr. Parekkadan’s interview at the World Advanced Therapies & Regenerative Medicine Congress in London here!
SEE VIDEO >

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

In September, our clinical trial was selected by Cell Trials Data as its Featured Advanced Cell Therapy Trial.
READ MORE >

Load More